News >

Published Data Back Regorafenib Dose Escalation in Colorectal Cancer

OncLive Staff
Published: Wednesday, Jul 03, 2019

Tanios Bekaii-Saab, MD

Tanios Bekaii-Saab, MD
A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer (mCRC), according to data from the phase II ReDOS trial now published in the Lancet Oncology.

 
Bekaii-Saab TS, Ou F-S, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study [published online June 28, 2019]. Lancet Oncol. doi:https://doi.org/10.1016/S1470-2045(19)30272-4.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x